270 related articles for article (PubMed ID: 29143681)
1. Economic evaluation of HCV testing approaches in low and middle income countries.
Morgan JR; Servidone M; Easterbrook P; Linas BP
BMC Infect Dis; 2017 Nov; 17(Suppl 1):697. PubMed ID: 29143681
[TBL] [Abstract][Full Text] [Related]
2. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
[TBL] [Abstract][Full Text] [Related]
3. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?
Martin NK; Boerekamps A; Hill AM; Rijnders BJA
J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25062. PubMed ID: 29633560
[TBL] [Abstract][Full Text] [Related]
4. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.
Martin NK; Vickerman P; Brew IF; Williamson J; Miners A; Irving WL; Saksena S; Hutchinson SJ; Mandal S; O'Moore E; Hickman M
Hepatology; 2016 Jun; 63(6):1796-808. PubMed ID: 26864802
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries.
Ishizaki A; Bouscaillou J; Luhmann N; Liu S; Chua R; Walsh N; Hess S; Ivanova E; Roberts T; Easterbrook P
BMC Infect Dis; 2017 Nov; 17(Suppl 1):696. PubMed ID: 29143609
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis.
Muller A; Vlahov D; Akiyama MJ; Kurth A
Int J Environ Res Public Health; 2020 Jul; 17(14):. PubMed ID: 32659974
[TBL] [Abstract][Full Text] [Related]
9. Respondent-driven sampling for identification of HIV- and HCV-infected people who inject drugs and men who have sex with men in India: A cross-sectional, community-based analysis.
Solomon SS; McFall AM; Lucas GM; Srikrishnan AK; Kumar MS; Anand S; Quinn TC; Celentano DD; Mehta SH
PLoS Med; 2017 Nov; 14(11):e1002460. PubMed ID: 29182638
[TBL] [Abstract][Full Text] [Related]
10. Who to screen for hepatitis C? A cost-effectiveness study in Belgium of comprehensive hepatitis C screening in four target groups.
Opstaele L; Bielen R; Bourgeois S; Moreno C; Nevens F; Robaeys G; Robaeys G; Van Vlierberghe H
Acta Gastroenterol Belg; 2019; 82(3):379-387. PubMed ID: 31566325
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups.
Falla AM; Hofstraat SHI; Duffell E; Hahné SJM; Tavoschi L; Veldhuijzen IK
BMC Infect Dis; 2018 Feb; 18(1):79. PubMed ID: 29433454
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update.
Han R; Zhou J; François C; Toumi M
BMC Infect Dis; 2019 Jul; 19(1):655. PubMed ID: 31337339
[TBL] [Abstract][Full Text] [Related]
13. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention.
Martin NK; Vickerman P; Dore GJ; Hickman M
Curr Opin HIV AIDS; 2015 Sep; 10(5):374-80. PubMed ID: 26248124
[TBL] [Abstract][Full Text] [Related]
14. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.
Hahné SJ; Veldhuijzen IK; Wiessing L; Lim TA; Salminen M; Laar Mv
BMC Infect Dis; 2013 Apr; 13():181. PubMed ID: 23597411
[TBL] [Abstract][Full Text] [Related]
15. Seroprevalence and burden of hepatitis C virus infection in WHO South-East Asia Region: A systematic review.
Goel A; Rewari BB; Sharma M; Konath NM; Aggarwal R
J Gastroenterol Hepatol; 2022 Jun; 37(6):964-972. PubMed ID: 35263807
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries.
Nayagam S; Sicuri E; Lemoine M; Easterbrook P; Conteh L; Hallett TB; Thursz M
BMC Infect Dis; 2017 Nov; 17(Suppl 1):692. PubMed ID: 29143675
[TBL] [Abstract][Full Text] [Related]
17. Model-based cost-effectiveness estimates of testing strategies for diagnosing hepatitis C virus infection in people who use injecting drugs in Senegal.
Duchesne L; Hejblum G; Toure Kane NC; Njouom R; Toni TD; Moh R; Sylla B; Rouveau N; Attia A; Lacombe K
Int J Drug Policy; 2020 Jan; 75():102613. PubMed ID: 31786434
[TBL] [Abstract][Full Text] [Related]
18. Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind.
Grillon C; Krishtel PR; Mellouk O; Basenko A; Freeman J; Mendão L; Andrieux-Meyer I; Morin S
J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25060. PubMed ID: 29633580
[TBL] [Abstract][Full Text] [Related]
19. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.
Degenhardt L; Peacock A; Colledge S; Leung J; Grebely J; Vickerman P; Stone J; Cunningham EB; Trickey A; Dumchev K; Lynskey M; Griffiths P; Mattick RP; Hickman M; Larney S
Lancet Glob Health; 2017 Dec; 5(12):e1192-e1207. PubMed ID: 29074409
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
